✦ LIBER ✦

The humoral response to human factor VIII in hemophilia A mice

✍ Scribed by J. F. HEALEY; E. T. PARKER; R. T. BARROW; T. J. LANGLEY; W. R. CHURCH; P. LOLLAR

Book ID: 118714720
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 751 KB
Volume: 5
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2007.02373.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Maternally transferred anti-factor VIII

Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice

✍ Yann Meslier; Sébastien André; Maud Teyssandier; Srinivas V. Kaveri; Sébastien L 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

Lack of response to commercial factor VI

Lack of response to commercial factor VIII concentrate in hemophilia a

✍ George M. Rodgers; Marilyn H. Ford 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Markers for the Factor VIII Antibody Res

Markers for the Factor VIII Antibody Response in Hemophilia A

✍ Shapiro, S S 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 370 KB

Comparative immunogenicity of recombinan

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII

✍ E. T. Parker; H. N. Craddock; R. T. Barrow; P. Lollar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB

Influence of aggregation on immunogenici

Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice

✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg

Effect of route of administration of hum

Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice

✍ Aaron Peng; Puneet Gaitonde; Matthew P. Kosloski; Razvan D. Miclea; Prashant Var 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,